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Abstract
Background: Aripiprazole can cause irreversible tardive dystonia in some individuals, and additional intervention
is sometimes needed. Here, we report the first case of aripiprazole-induced irreversible tardive dystonia in which
complete recovery of motor function was achieved using the antipsychotic drug clozapine.
Case presentation: A 24-year-old man with bipolar disorder was treated with aripiprazole and gradually developed
tardive dystonia. Thorough medical and neurological examinations were performed to rule out other possible causes
of tardive dystonia. Clozapine was administered when the patient did not improve following long-term withdrawal of
aripiprazole or adjuvant medications. Before administration of clozapine, the patient was experiencing severe dystonia
as assessed by the Extrapyramidal Symptom Rating Scale. Dystonic symptoms began to improve about 1 month after
starting administration of clozapine and were completely resolved 3 months after clozapine administration.
Conclusions: Clinicians should note the risk of aripiprazole-induced tardive dystonia and consider clozapine as an
alternative and effective treatment modality in cases of irreversible tardive dystonia, particularly when concomitant
treatment of psychotic symptoms is required.
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Background
Tardive dystonia is a serious movement disorder that
occurs in patients treated with antipsychotics [1], and
has been shown to develop in about 3 % of patients who
have had long-term exposure to antipsychotics [2]. If un-
treated, this condition can often cause considerable
distress and can lead to permanent debilitation [3, 4].
Chronic dopamine receptor antagonism is known to be
strongly associated with the manifestation of tardive
dystonia symptoms [5]. The low risk of tardive dystonia
for atypical antipsychotics is thought to result from their
weak affinity for dopamine receptors [6, 7].
Aripiprazole is an atypical antipsychotic with unique
pharmacological properties. Because of its partial antag-
onistic activity on dopamine D2 receptors, aripiprazole
is associated with an especially low risk of developing
tardive dystonia. Moreover, some reports have described
the use of aripiprazole in the treatment of tardive
dystonia [8, 9]. Nonetheless, aripiprazole has also been
shown to cause tardive dystonia in some cases, and motor
symptoms of aripiprazole-induced tardive dystonia can
sometimes be reversed by withdrawal of aripiprazole and
addition of anticholinergic medications [10–13]. However,
in some cases, neither withdrawal of medication nor treat-
ment with drugs, such as trihexyphenidyl, have been
shown to be effective in alleviating symptoms [10, 14, 15].
Some studies have reported improvement in symp-
toms of tardive dystonia by switching from a typical
antipsychotic to an atypical antipsychotic [16], such as
clozapine. However, attempts to assess the efficacy of
clozapine on motor symptoms in patients with tardive
dystonia are conflicting and inconclusive. Many previous
studies examining the effects of switching to clozapine
for antipsychotic-induced tardive dystonia have reported
a reversal of motor symptoms [17, 18]. However, it is
not clear whether discontinuation of the original anti-
psychotic treatment or the switch to clozapine leads to
improvements in movement symptoms.
Here, we present the first case of an aripiprazole-treated
patient who developed tardive dystonia and experienced
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reversal of symptoms with clozapine treatment. The
patient gave written informed consent for publication.
Case presentation
Mr. A, a 24-year-old man with bipolar disorder, pre-
sented with irritable mania in July 2009. His father had
schizophrenia, and his sister had a schizoaffective dis-
order. He had never taken antipsychotics prior to this
manic episode. Aripiprazole (5 mg/d) was administered
to manage the manic symptoms, and gradual titration
was tried. However, the patient and his family refused to
take more than 5-mg aripiprazole because of a concern
of adverse events by dose escalation. His manic symp-
toms slightly improved by December 2009. Though he
was still manic, he was not aggressive enough to be sui-
cidal or violent. Between September and October 2010,
an agreement was obtained from the patient and his
family for dose escalation, and gradual titration up to
15 mg/d was achieved by October 2010. The patient’s
manic symptoms were partially remitted by December
2010, and sodium valproate was later added to the treat-
ment strategy in August 2011 (titrated to 800 mg/d by
November 2011) to improve residual manic symptoms.
Propranolol (20 mg/d) was also added to the treatment
regimen because the patient complained of a twitching
sensation in the periocular area (September 2011). Pro-
pranolol was titrated up to 40 mg/d by December 2011,
and the patient reported improvement in his twitching
symptom (January 2012).
In July 2012, 3 years after the initiation of drug treat-
ment, the patient began complaining of neck stiffness.
By this time, he was taking daily doses of aripiprazole
(15 mg), sodium valproate (800 mg), and propranolol
(30 mg). He was not taking any other medication that
could potentially cause tardive dystonia, including herbal
medication, within 1 month before dystonia developed.
Benztropine (4 mg) and valium (2 mg) were prescribed
to treat his neck stiffness, but these were not effective.
By September 2012, he had gradually developed cervical
dystonia with right-side convexity and neck hyperexten-
sion. The patient could voluntarily reposition himself at
first. However, 1 month later, this had become impos-
sible. His symptoms satisfied the following diagnostic
criteria for tardive dystonia [19]: (1) he had dystonia; (2)
he developed dystonia during antipsychotic treatment;
(3) Wilson’s disease was ruled out, and there were no
other neurological signs to suggest one of the many
causes of secondary dystonia; (4) there was no family
history for dystonia. He showed slight abnormalities in
liver function (Aspartate transaminase 27 IU/L, Alanine
transaminase 52 IU/L), ceruloplasmin (15 mg/dL), and
24-h urine copper tests (77.99 μg/day); however, further
studies, including ultrasonography of the liver and oph-
thalmologic examination did not reveal or confirm
Wilson’s disease. Otherwise, there were no abnormal
findings on hematology tests, biochemistry tests, or
serum valproate levels. A thorough neurologic examin-
ation confirmed that he had no other movement disor-
ders. No abnormalities were detected in brain magnetic
resonance imaging (MRI).
Aripiprazole was continued for about 6 months even
after the onset of dystonia, because he and his family
refused to change medication because of fear of adverse
events by new medication. Because his dystonia became
worse as time progressed we decided to discontinue aripi-
prazole. The daily dose of aripiprazole was tapered and dis-
continued over 11 weeks after the appearance of torticollis.
By January 2013, administration of aripiprazole ceased
completely. The patient reported experiencing an irritable
mood and frequent anger outbursts in February 2013. No
other accompanying tardive syndromes other than neck
tardive dystonia were observed in this patient. To treat
tardive dystonia and to prevent relapse of mania, clozapine
treatment was recommended to the patient in March
2013; however, he refused to take clozapine because of fear
of developing agranulocytosis. By April 2013 the patient
was experiencing severe dystonia (Score of Dystonia = 10)
based on the Extrapyramidal Symptom Rating Scale
(ESRS). Despite withdrawal from aripiprazole, the dystonic
symptoms persisted, and the index of severity, measured
by the ESRS, was unchanged, even 8 months after
complete discontinuation of aripiprazole. His neck dystonia
caused severe distress and impaired social and occupa-
tional function. He was concerned about what people
would think about his posture, and tended to stay home
from work and social events. He ultimately quit his pos-
ition at his university. Moreover, the patient continued to
experience fluctuating irritability and uncontrolled anger.
We decided to administer clozapine for the treatment
of tardive dystonia because it was a promising candidate
for improving motor symptoms [14, 20] and was ex-
pected to control his manic symptoms. The potential
efficacy of clozapine in treating aripiprazole-induced
tardive dystonia had not yet been previously reported.
The starting dose of clozapine was 12.5 mg/day, and the
dose was gradually titrated weekly up to 87.5 mg/day
until August 2013. Dystonic symptoms began to improve
1 month after clozapine was started, and tardive dys-
tonia was completely resolved 3 months after clozapine
administration was started (September 2013). His ESRS
score reached zero. At that time, the dose of clozapine
was 87.5 mg/day. Additionally, by November 2013 his
manic symptoms dramatically improved, and his daily
dose of clozapine was 100 mg/d.
Conclusions
In the present case, the occurrence of tardive dystonia in
an antipsychotic-naïve patient strongly suggested that
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aripiprazole was the causal agent. While he showed tard-
ive dystonia, his father and sister, who are on other anti-
psychotics, did not experience tardive dystonia, and
thus, there is no history of familial dystonia. To our
knowledge, concomitant medications, i.e., sodium val-
proate and propranolol, have not been reported to cause
tardive dystonia, and in fact, valproate was reported to
improve tardive syndrome in an open trial [20]. Neuro-
logic examinations did not show other causes of dys-
tonia. This patient has several well-known risk factors,
e.g., young, male, and was diagnosed with affective dis-
order [1]. Several hypotheses, such as interactions
between antipsychotics and antidepressants, or short-
term use of high dose antipsychotics in affective disorder
have been suggested for high risk of tardive dystonia in
affective disorder [21]. Among them, vulnerability of the
brain due to cyclic mono- and catecholamine activity
during mood swings may account for tardive dystonia in
this case.
This patient was a good candidate for clozapine ther-
apy because he needed medication to concurrently
improve tardive dystonia and to alleviate his manic
symptoms. Other therapies for tardive dystonia are not
known to be effective in manic symptoms. In addition,
he is young and duration of tardive dystonia was rela-
tively short (about 8 months). In a recent review, cloza-
pine was reported to be more beneficial in treating
tardive dystonia in patients who are young and have
shorter duration [22]. In this case, tardive dystonia per-
sisted and was unchanged for a relatively long period,
despite withdrawal of aripiprazole, and the symptoms
were rapidly and completely reversed after clozapine
administration. This indicates that clozapine reversed
aripiprazole-induced tardive dystonia in this case.
Previous case studies [10, 14] reported that antipsychotic-
naïve patients developed aripiprazole-induced tardive dys-
tonia (Table 1). Among them, spontaneous reversal of
tardive dystonia symptoms by antipsychotic withdrawal and
the passage of time occurred in only one case [10]. In
another case, dystonia persisted for over 18 months,
and medications, including trihexyphenidyl and botu-
linum toxins, were not effective in alleviating symp-
toms. Deep brain stimulation therapy finally produced
an improvement in this patient [10]. In another case,
dystonia was reported to have persisted over a 2-month
observation period [14].
Withdrawal of aripiprazole alone was not enough to
reverse tardive dystonia in previous cases [10, 11, 14].
Trihexyphenidyl and quetiapine were used in those
cases. However, it is not clear whether the medication or
withdrawal of aripiprazole reversed the motor symp-
toms. Unlike previous reports, the present case study
had a relatively long interval between withdrawal of aripi-
prazole and the onset of clozapine administration, sup-
porting the idea that clozapine exerted therapeutic effects
in aripiprazole-induced tardive dystonia. Although the use
of clozapine has some limitations because of the risk of
agranulocytosis, it can be an effective alternative treatment
in the management of irreversible tardive dystonia.
The exact pathophysiology of tardive dystonia remains
uncertain. Tardive dystonia has been ascribed to supersen-
sitivity of dopamine receptors, particularly D2, after long-
term blockade [22]. However, this may not be the only
explanation for the development of tardive dystonia.
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Imbalance between direct and indirect pathways of the
basal ganglia was recently mentioned as an underlying
mechanism for tardive dystonia [23]. In addition, mal-
adaptive synaptic plasticity in corticostriatal transmission
and oxidative stress, both provoked by chronic D2 block-
ade, were proposed to be responsible for tardive dystonia
[24, 25]. Also 5-HT2A/2C receptors are probably involved
in the pathogenesis of tardive dystonia [26]. 5-HT2A and
5-HT2c antagonism enhance dopamine release, and the
low risk of tardive dystonia by clozapine and quetiapine is
attributed to these properties.
The relatively low risk of tardive dystonia with aripi-
prazole is attributed to the unique partial agonistic activ-
ity on D2 receptor [18]. However, aripiprazole has one
of the highest D2 receptor affinities at a therapeutic dose
[18]. Theoretically, long-term exposure of aripiprazole to
D2 receptors may cause irreversible hypersensitivity of
D2 receptors. A model explaining the development of
the tardive syndrome suggests that chronic D2 (indirect
inhibitory pathway) receptor occupancy by long term
antipsychotic medication may sensitize D1 receptors and
may lead to an imbalance of D1 and D2 striatal outputs.
According to this model, a D1 antagonist may be an
effective treatment for tardive syndrome [27]. Clozapine
has relatively high D1 and low D2 receptor occupancy.
[28]. This may explain the efficacy of clozapine for tard-
ive dystonia in our case. Also, aripiprazole has partial
antagonistic properties at 5-HT2A/2C receptors, which
is very unique and another difference of aripiprazole
and clozapine. This may be involved in reversal of aripi-
prazole induced tardive dystonia by clozapine in this
case. [29].
To date, there is no established treatment to cure this
severe form of movement disorder [22]. This case report
suggests that clozapine may be effective in treating irre-
versible aripiprazole-induced tardive dystonia. Because
this is a case report, overgeneralization of the results
should be avoided, and more systematic research, such
as randomized, controlled, blinded studies, should be
carried out. As a relatively new antipsychotic, the thera-
peutic indications of aripiprazole are broadening, and
the occurrence of tardive dystonia among patients taking
aripiprazole may increase. Clinicians should be aware of
the risk of aripiprazole-induced tardive dystonia and
should consider clozapine treatment in irreversible
cases, especially when concomitant treatment for psych-
otic symptoms is needed.
Consent
The patient has given his written informed consent for
this case report to be published. Before he gave his writ-
ten informed consent for this case report to be pub-
lished, he was in healthy enough mental and physical
condition that would have allowed them to provide
informed consent for publication with his free will, good
enough intelligence for decision making ability and clear
consciousness.
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